BMRN
Biomarin Pharmaceutical Inc
NASDAQ: BMRN · HEALTHCARE · BIOTECHNOLOGY
$54.21
+1.71% today
Updated 2026-04-29
Market cap
$10.48B
P/E ratio
30.12
P/S ratio
3.25x
EPS (TTM)
$1.80
Dividend yield
—
52W range
$51 – $66
Volume
2.0M
Biomarin Pharmaceutical Inc (BMRN) Financial statements
SEC filings — annual and quarterly data.
Profit margin
10.80%
Operating margin
22.50%
ROE
5.94%
ROA
5.58%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $84.21M | $-28.53M | 89.62% | -29.30% | -33.88% |
| 2007 | $121.58M | $-15.80M | 84.90% | -47.12% | -13.00% |
| 2008 | $296.49M | $30.83M | 82.29% | 13.41% | 10.40% |
| 2009 | $324.66M | $-488000.00 | 79.70% | 5.06% | -0.15% |
| 2010 | $376.27M | $205.82M | 81.32% | 0.14% | 54.70% |
| 2011 | $441.36M | $-53.84M | 80.96% | -7.68% | -12.20% |
| 2012 | $500.72M | $-114.35M | 81.66% | -22.01% | -22.84% |
| 2013 | $548.49M | $-176.35M | 83.88% | -28.44% | -32.15% |
| 2014 | $749.28M | $-133.97M | 83.68% | -12.40% | -17.88% |
| 2015 | $889.89M | $-171.80M | 82.92% | -12.44% | -19.31% |
| 2016 | $1.12B | $-630.21M | 81.23% | -71.94% | -56.43% |
| 2017 | $1.31B | $-117.04M | 81.59% | -1.12% | -8.91% |
| 2018 | $1.49B | $-77.21M | 78.86% | -8.28% | -5.18% |
| 2019 | $1.70B | $-23.85M | 78.91% | -5.90% | -1.40% |
| 2020 | $1.86B | $854.03M | 71.82% | -2.33% | 45.90% |
| 2021 | $1.85B | $-64.08M | 74.52% | -4.46% | -3.47% |
| 2022 | $2.10B | $141.56M | 76.00% | 7.68% | 6.75% |
| 2023 | $2.42B | $167.65M | 78.01% | 7.68% | 6.93% |
| 2024 | $2.85B | $426.86M | 79.67% | 16.97% | 14.96% |
| 2025 | $3.22B | $348.90M | 77.13% | 16.56% | 10.83% |